current
issue
1/2014

Zaburzenia metabolizmu glukozy w populacji wieku rozwojowego – co nowego w diagnostyce i leczeniu? Część II

© Borgis - Medycyna Rodzinna 1, p. 19-23
*Ewa Otto-Buczkowska, Przemysława Jarosz-Chobot
Zaburzenia metabolizmu glukozy w populacji wieku rozwojowego – co nowego w diagnostyce i leczeniu? Część II
Alterations of blood glucose homeostasis in children and adolescents – what news in diagnostics and therapy? Part II
Górnośląskie Centrum Zdrowia Dziecka i Matki, Poradnia Diabetologiczna, Katowice
Summary
Secondary diabetes may occur in association with endocrine or nonendocrine disorders. The most common endocrine diseases associated with glucose intolerance are those involving overproduction of counterregulatory hormones. Diabetes frequently coexists with altered function of the pituitary, adrenal and thyroid glands and gonads.
Corticosteroids induce a state of insulin resistance characterized by decreased binding of insulin to insulin receptors and decreased utilization of glucose. These agents also increase hepatic gluconeogenesis by enhancing the activity of gluconeogenic enzymes and by increasing the availability of gluconeogenic substracts.
Diabetes mellitus not infrequently coexists with hypo- and hyperthyroidism. Thyroid hormone causes a decrease in glucose-induced insulin secretion. Abnormal glucose metabolism with impaired glucose tolerance has been documented in patients with thyrotoxicosis Thyrotoxicosis causes dramatic increase of glycogen degradation and/or gluconeogenesis.
Nonendocrine conditions associated with glucose intolerance or diabetes fall into three general categories: pancreatic diseases, drug-induced diabetes and genetic syndromes.
The therapy for secondary diabetes centers on the correction of underlying disturbance. Patients with fasting hyperglycemia should be treated with an understanding of the pathophisiologic basis of their diabetes.
Stress that follows critical states may lead to a profound impairment of that homeostasis, including occurrence of hyperglycemia.
Hyperglycemia is a common feature of the critically ill patient and has been associated with increased mortality. It does not appear to be associated with a particular diagnostic category but is significantly associated with severity of illness. Severe hyperglycemia may be associated with complications, this in turn could result in end-organ dysfunction. Prevention of glucose toxicity by strict glycemic control but also other metabolic and non-metabolic effects of insulin contribute to these clinical benefits. Continuous insulin infusion can rapidly and safely improve intravenous glucose tolerance.
Key words: glucose homeostasis, impaired glucose tolerance, hyperglycemia, decreased peripheral glucose utilization, secondary diabetes, endocrine disorders, overproduction of counterregulatory hormones, genetic syndromes, pancreatic diseases, drug-induced diabetes
Piśmiennictwo
1. Otto-Buczkowska E., et al.: Cukrzyca wtórna. Medycyna Metaboliczna 2003; 7: 49-56. 2. Jarosz-Chobot P, Otto-Buczkowska E.: Hormonalna regulacja homeostazy glukozy. Hiperglikemia. w Endokrynologia wieku rozwojowego - co nowego? Otto-Buczkowska E. (red.) Cornetis, Wrocław 2008. 3. Krassowski J.: Wtórne zaburzenia tolerancji glukozy w przebiegu endokrynopatii. w Cukrzyca - patogeneza, diagnostyka, leczenie. Otto-Buczkowska E. (red.) Borgis, Warszawa 2005: 176-189. 4. Otto-Buczkowska E., et al.: Współwystępowania autoimmunologicznych schorzeń tarczycy z cukrzycą typu 1 u młodocianych chorych. Lekarz 2006; 10: 37. 5. Branco R.G., et al.: Hyperglycemia, glycemic control, glucose level, insulin therapy, intensive care, pediatric. J. Pediatr., (Rio J). 2007; 83, 5 Suppl.: S128-136. 6. Otto-Buczkowska E., et al.: Alterations of blood glucose homeostasis in critically ill children - hyperglycemia. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw., 2007; 13: 43-46. 7. Otto-Buczkowska E, Szirer G.: Zaburzenia homeostazy glukozy u chorych znajdujących się w stanie krytycznym. w Pediatria - co nowego? Otto-Buczkowska E. (red.), Cornetis, Wrocław 2007: 397-405. 8. Beardsall K., et al.: Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants. J. Pediatr., 2007, 151, 611-617. 9. Kairamkonda V.: Does continuous insulin infusion improve glycaemic control and nutrition in hyperglycaemic very low birth weight infants? Arch. Dis. Child., 2006; 91: 76-79. 10. Roberson J.R., et al.: Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008; 11 (Epub ahead of print). 11. Otto-Buczkowska E., et al.: Nowoczesne metody leczenia i monitorowania cukrzycy typu 1. Endokrynol. Pol., 2008. 12. Kane M.P., et al.: The utility of oral diabetes medications in type 2 diabetes of the young. Curr. Diabetes Rev., 2005; 1: 83-92. 13. Otto-Buczkowska E., et al.: Czy doustne leki przeciwcukrzycowe znajdują zastosowanie w leczeniu młodocianych. Przegl. Lek., 2008. 14. The TODAY Study Group, Zeitler P., et al.: Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr. Diabetes., 2007; 8: 74-87. 15. Codner E., et al.: Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycaemia, hypoglycaemia and sickdays. Diabetes Care. 2007; 30(5): e28-29. 16. Małecki M.T., Klupa T.: Rzadkie formy cukrzycy u dzieci i młodzieży. Przew. Lek., 2006; 3: 20-28. 17. Sagen J.V., et al.: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53: 2713-2718. 18. Zung A., et al.: Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab., 2004; 89: 5504-5507.

otrzymano/received: 2007-12-14
zaakceptowano/accepted: 2007-12-27

Adres/address:
*Ewa Otto-Buczkowska
Jasnogorska 16/21, 44-100 Gliwice
e-mail: em.buczkowski@pro.onet.pl
Copyright © Borgis Medical Publisher Ltd. 2007-2014